Galderma Sales Top $1 Billion, Led By Injectables

The public company reported strong sales, as demand for its dermatological skincare and injectable products surged.

Year-on-year growth was reported in all categories, with a 19.3 percent increase in injectables, 8.4 percent spike in dermatological skincare and 4 percent growth for therapeutic products.

Within the injectables category, sales of neuromodulators (such as Botox alternative Dysport), were $263 million, up 20.4 percent, while fillers and biostimulators were $248 million, up 18.2 percent. The growth was mainly led by volume, as demand for so-called “tweakments”, or minimally invasive procedures continues to rise. Dermatological skincare sales, led by affordable brand Cetaphil, were $351 million, with global expansion in Asia, as well as marketing efforts tied to New York Fashion Week and the Super Bowl were noted as growth drivers.

Luiz Inácio Lula da Silva:
Ms. Court we are waiting, are you behind on the paperwork? Hurry.
We want to see that fantasy.

About The Author

Catherine Zielinski

Mrs. Zielisnki is tasked with implementing winning strategies and the breakthrough strategic learning process of the magazine. She stands on her writing about anything.

See author's posts